Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

Pre-registration for:
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

Sunday, September 28, 2025

Hilton Minneapolis Grand
Ballroom C Hilton Minneapolis
1001 Marquette Avenue
South Minneapolis, Minnesota

Register using the form provided below. Click HERE for additional meeting details.
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Around 50% of patients experience heart failure (HF) symptoms/signs in the presence of a preserved left ventricular ejection fraction, and half of these patients have increased left ventricular wall thickness. Transthyretin amyloid cardiomyopathy (ATTR-CM), a restrictive cardiomyopathy resulting from the deposition of amyloid fibrils in the interstitial space of the heart muscle, commonly fits these characteristics. ATTR-CM has been increasingly recognized as a much more frequent cause of HF than previously thought; it is a progressive and fatal condition if not diagnosed promptly. Multiple disease-modifying therapies for ATTR-CM are now available, and other treatments are under investigation. However, the condition remains misdiagnosed and underdiagnosed since awareness of the disease among clinicians and in the community is less than optimal. In this symposium, Chair Dr. Mathew Maurer, and faculty members Dr. Noel Dasgupta, Dr. Omar Abou Ezzeddine, and Dr. Frederick Ruberg, will explain best practices for screening and diagnosing ATTR-CM in patients with concomitant HF, describe the treatment landscape, and, through case presentation, discuss practical considerations in management.

Educational Objectives:

  • Identify red flags which raise suspicion for ATTR-CM in HF patients.
  • Discuss the diagnostic tests to quickly and accurately diagnose ATTR-CM.
  • Explain the evidence and effectiveness of traditional HF medications in patients with ATTR-CM.
  • Summarize the evolving landscape for ATTR-CM therapies.
  • Recognize how patient monitoring and assessment is constantly changing and improving.

Target Audience:

This educational activity is intended for clinicians who manage patients with heart failure.

Accreditation and Credit Designation Statements

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Grant:

Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peerreviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 1 Bethany Rd. Bldg 3, Suite 48, Hazlet, NJ 07730. Phone: 973-467-0500